Robert Boolbol, MD
Interventional Pain Medicine · Farmington, CTNPI 1316935034
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 995 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.
Across 995 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Scilex Pharmaceuticals Inc.$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Collegium Pharmaceutical, Inc.$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$610
- plus $5K from 44 others
What the payments were for
- Food & beverage$15,381100%
- Education$750%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few interventional pain medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dermacinrx LidocanLidocaine | 49 | $79,034 |
| RelistorMethylnaltrexone Bromide | 22 | $53,706 |
| Cyclobenzaprine Hcl | 432 | $43,650 |
| Lidocaine | 385 | $28,025 |
| BelbucaBuprenorphine Hcl | 30 | $16,855 |
| OxycontinOxycodone Hcl | 39 | $14,603 |
| Oxycodone Hcl | 790 | $13,892 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 394 | $10,187 |
| LinzessLinaclotide | 14 | $8,384 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 298 | $8,245 |
| Xtampza ErOxycodone Myristate | 15 | $5,854 |
| Celecoxib | 211 | $5,273 |
| Etodolac | 69 | $5,165 |
| Gabapentin | 270 | $4,879 |
| Pregabalin | 141 | $3,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,478 | $53,70622 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $1,937 | $22,71045 claims |
| AbbVieLinzess | $1,278 | $8,38414 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Morphine Sulfate | $113 | $6,932117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain medicine providers in Connecticuton file to place this against a meaningful peer group, so we don't.
Other interventional pain medicine in Farmington
- Roshni PatelFarmington$3K
- Richard LucarelliVernon$71K
- Mohan VodapallyHamden$26K
- Mark ThimineurDerby$17K
- Shyam DesaiFairfield$14K
- Michael GrilleHartford$10K
- Jonathan KostWest Hartford$10K
- Pardeep SoodTrumbull$8K
- Vincent CarlesiDanbury$8K
- Dwight LighamNew Haven$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.